Reviewing Quantum Biopharma (QNTM) & Its Competitors

Institutional and Insider Ownership

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Quantum Biopharma and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Quantum Biopharma	N/A	-$17.90 million	-0.23
Quantum Biopharma Competitors	$2.14 billion	$158.33 million	-5.73

Quantum Biopharma’s peers have higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Quantum Biopharma has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Quantum Biopharma’s peers have a beta of 3.82, meaning that their average stock price is 282% more volatile than the S&P 500.

Profitability

This table compares Quantum Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-84.21%	-62.63%
Quantum Biopharma Competitors	-3,419.61%	-220.74%	-32.93%

Summary

Quantum Biopharma peers beat Quantum Biopharma on 6 of the 9 factors compared.

Quantum Biopharma Company Profile

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.